Resistance to chemotherapy via Stat3-dependent overexpression of Bcl-2 in metastatic breast cancer cells - PubMed (original) (raw)

. 2002 Oct 31;21(50):7611-8.

doi: 10.1038/sj.onc.1206004.

Affiliations

• PMID: 12400004
• DOI: 10.1038/sj.onc.1206004

Resistance to chemotherapy via Stat3-dependent overexpression of Bcl-2 in metastatic breast cancer cells

Pedro J Real et al. Oncogene. 2002.

Abstract

Disruption of apoptosis may allow metastatic cell survival and confer resistance to chemotherapeutic drugs. We have analysed the molecular pathways that activate these survival genes in specific sites of metastasis. Estrogen receptor-negative breast cancer cell line MDA-MB435 and two metastatic sublines derived from lung (435L) and brain (435B) were analysed for the expression of members of the Bcl-2 family of apoptosis regulators. The levels of Bcl-2 were higher in the metastatic sublines than in parental cells, which correlated with the activation of Stat3, but not with the expression and/or activation of known bcl-2 transcription factors (CREB and WT1). In the brain subline, both expression of Bcl-2 and Stat3 activation were induced by epidermal growth factor and abrogated after treatment with kinase inhibitors specific for epidermal growth factor receptor or Jak2. Furthermore, transfection of 435B with a dominant-negative Stat3 markedly reduced the expression of Bcl-2 protein, whereas transient expression of a constitutively active Stat3 increased Bcl-2 in parental 435 cells. In addition, blockade of Stat3 activation by treatment with epidermal growth factor receptor and Jak2 kinase inhibitors or transfection with a dominant negative Stat3, sensitizes 435B cells to chemotherapy-induced apoptosis. Our data suggest that an increased activation of the Stat3-Bcl-2 pathway in estrogen receptor-negative metastatic breast cancer cell lines confer a survival advantage to these cells and contribute to their chemoresistance.

PubMed Disclaimer

Similar articles

• Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells.
  Song L, Turkson J, Karras JG, Jove R, Haura EB. Song L, et al. Oncogene. 2003 Jul 3;22(27):4150-65. doi: 10.1038/sj.onc.1206479. Oncogene. 2003. PMID: 12833138
• Inhibition of Stat3 increases doxorubicin sensitivity in a human metastatic breast cancer cell line.
  Gariboldi MB, Ravizza R, Molteni R, Osella D, Gabano E, Monti E. Gariboldi MB, et al. Cancer Lett. 2007 Dec 18;258(2):181-8. doi: 10.1016/j.canlet.2007.08.019. Epub 2007 Oct 24. Cancer Lett. 2007. PMID: 17920763
• Inhibition of constitutively active Stat3 suppresses growth of human ovarian and breast cancer cells.
  Burke WM, Jin X, Lin HJ, Huang M, Liu R, Reynolds RK, Lin J. Burke WM, et al. Oncogene. 2001 Nov 29;20(55):7925-34. doi: 10.1038/sj.onc.1204990. Oncogene. 2001. PMID: 11753675
• Regulation of Bcl-xL: a little bit of this and a little bit of STAT.
  Grad JM, Zeng XR, Boise LH. Grad JM, et al. Curr Opin Oncol. 2000 Nov;12(6):543-9. doi: 10.1097/00001622-200011000-00006. Curr Opin Oncol. 2000. PMID: 11085453 Review.
• Resistance to antineoplastic therapy. The oncogenic tyrosine kinase-Bcl-x(L) axis.
  Weintraub SJ, Manson SR, Deverman BE. Weintraub SJ, et al. Cancer Cell. 2004 Jan;5(1):3-4. doi: 10.1016/s1535-6108(03)00338-6. Cancer Cell. 2004. PMID: 14749119 Review.

Cited by

• Ponicidin induces apoptosis via JAK2 and STAT3 signaling pathways in gastric carcinoma.
  Liu YF, Lu YM, Qu GQ, Liu Y, Chen WX, Liao XH, Kong WM. Liu YF, et al. Int J Mol Sci. 2015 Jan 12;16(1):1576-89. doi: 10.3390/ijms16011576. Int J Mol Sci. 2015. PMID: 25588213 Free PMC article.
• A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells.
  Song H, Wang R, Wang S, Lin J. Song H, et al. Proc Natl Acad Sci U S A. 2005 Mar 29;102(13):4700-5. doi: 10.1073/pnas.0409894102. Epub 2005 Mar 21. Proc Natl Acad Sci U S A. 2005. PMID: 15781862 Free PMC article.
• Bcl-x(L)-mediated changes in metabolic pathways of breast cancer cells: from survival in the blood stream to organ-specific metastasis.
  España L, Martín B, Aragüés R, Chiva C, Oliva B, Andreu D, Sierra A. España L, et al. Am J Pathol. 2005 Oct;167(4):1125-37. doi: 10.1016/S0002-9440(10)61201-1. Am J Pathol. 2005. PMID: 16192647 Free PMC article.
• A novel small molecule, LLL12, inhibits STAT3 phosphorylation and activities and exhibits potent growth-suppressive activity in human cancer cells.
  Lin L, Hutzen B, Li PK, Ball S, Zuo M, DeAngelis S, Foust E, Sobo M, Friedman L, Bhasin D, Cen L, Li C, Lin J. Lin L, et al. Neoplasia. 2010 Jan;12(1):39-50. doi: 10.1593/neo.91196. Neoplasia. 2010. PMID: 20072652 Free PMC article.
• A small molecule, LLL12 inhibits constitutive STAT3 and IL-6-induced STAT3 signaling and exhibits potent growth suppressive activity in human multiple myeloma cells.
  Lin L, Benson DM Jr, DeAngelis S, Bakan CE, Li PK, Li C, Lin J. Lin L, et al. Int J Cancer. 2012 Mar 15;130(6):1459-69. doi: 10.1002/ijc.26152. Epub 2011 Aug 26. Int J Cancer. 2012. PMID: 21520044 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Nature Publishing Group

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information

• Molecular Biology Databases

  • BioCyc

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal